Regeneron Pharmaceuticals (REGN) Rallies 27.4% on Strong Pipeline and Earnings

Regeneron Pharmaceuticals shares have risen 27.4% over the past month, outperforming the broader industry's 10.9% advance as well as the S&P 500 Index. The upward movement follows the release of early-stage clinical trial results and strong third-quarter earnings. In newly reported first-in-human trial data for its investigational CIDEBsiRNA drug candidate targeting metabolic dysfunction-associated steatohepatitis (MASLD), a single subcutaneous dose led to liver fat reductions of 58% to 80% at week 36, alongside sustained improvements in liver injury markers and a safety profile comparable to placebo.

The company's commercial performance has been supported by solid third-quarter results. Revenue climbed 36.3% year over year to $5.12 billion, topping consensus estimates of $4.58 billion. Earnings per share reached $20.07, surpassing analyst expectations of $16.51 and up from $11.83 during the prior-year period. Full-year earnings per share expectations have climbed north to $67.45 over the last 30 days, while 2027 estimates rose to $72.94, according to recent tracking data.

Higher sales of Eylea HD helped cushion an ongoing drop in standard Eylea revenues caused by biosimilar competition and rival therapies like Roche's Vabysmo. Eylea HD generated $699 million in third-quarter U.S. sales, representing a 62% jump year over year. In April 2026, the FDA cleared extended dosing intervals for Eylea HD of up to every 20 weeks, and Regeneron anticipates a regulatory decision regarding a prefilled syringe version before the end of the year.

Growth in profit-sharing from Dupixent, marketed with partner Sanofi, also contributed to overall earnings momentum. In October 2026, the two companies broadened their collaboration to develop four next-generation long-acting antibodies, giving Regeneron an upfront payment of $1 billion with potential milestones of up to $7 billion. Looking ahead to pipeline milestones, Regeneron expects an FDA decision later in November on cemdisiran for generalized myasthenia gravis.

Wall Street analysts maintain a consensus Moderate Buy rating on REGN shares, with an average target price of $898.97, according to MarketBeat. Regeneron also announced a quarterly dividend of $0.94 per share payable on December 3 to shareholders of record as of November 20, following an $839.5 million share repurchase. Concurrently, corporate insiders disposed of 28,228 shares worth approximately $26.0 million across the past 90 days, while institutional investors retain an 83.31% stake in the firm.